2022 World Conference on Lung Cancer (ePosters)-EP08.01-022. Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events

EP08.01-022. Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events

Back to course

Pdf Summary

This study aimed to assess the use and outcomes of second-line immune modulators in patients with advanced lung cancer and malignant melanoma who experienced severe immune-related adverse events (irAEs) that did not respond to steroids. A retrospective study was conducted on patients who started immune checkpoint inhibitors (ICI) at three tertiary cancer centers. Among a total of 654 patients, 56 patients (8.6%) were identified as having received both steroids and second-line immunosuppressants for severe irAEs. The majority of patients had non-small cell lung cancer (NSCLC), followed by malignant melanoma. The most common irAEs included colitis, pneumonitis, hepatitis, neuromuscular, and myocarditis. Improvement was observed in patients with hepatitis and colitis, but less so in those with neuromuscular and pneumonitis. The use of second-line immunosuppressants resulted in heterogeneous responses, with some patients remaining refractory and experiencing toxicities from immunosuppression. The study concludes that treatment options for severe irAEs are limited and not well-defined, highlighting the need for personalized immunomodulatory treatments to guide biologically-informed therapies for these events.

Asset Subtitle

Yasar Ahmed

Meta Tag

Speaker Yasar Ahmed

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

advanced lung cancer

malignant melanoma

immune-related adverse events

steroids

retrospective study

immune checkpoint inhibitors

non-small cell lung cancer

colitis

pneumonitis

hepatitis